Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046054/SGN-PDL1V in advanced solid tumors
NL-OMON60478Phase 1Recruiting
- Sponsor
- Seagen Inc.
- Start
- Feb 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGN-PDL1V in triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 5 more, sponsored by Seagen Inc. Primary endpoint: Primary endpoint(s). Started Feb 2023; status: recruiting.
02
Drugs
SGN-PDL1V
03
Conditions
triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)gastric cancer (GC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON60478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60478.